Abstract
Inflammatory and autoimmune diseases are classically considered as disorders arising from hyper-activation of immunity and hence are treated with drugs that suppress the lymphocyte activation and inflammation. Although this strategy has proven useful to cure symptoms, it rarely can heal the disease and long-term treatments are usually needed. Inflammatory and autoimmune diseases frequently occur also in patients with primary immune deficiency disease, proving that immune hyper-activation may paradoxically arise from defective function of immune genes. In these cases, the phenotype of hyper-activation is believed to reflect the attempts of the immune system to compensate for immune defects. Recent data suggest that similar mechanisms could be involved also in the pathogenesis of some multifactorial disorders, such as Crohn’s disease and systemic lupus erythematosus. Based on these considerations, novel therapies could be developed to cure severe autoimmune and inflammatory disorders, not only by aiming to hyper-activation but as well by focusing on the possible underlying immune defects.
Keywords: Primary immunodeficiency diseases, anti-inflammatory drugs, inflammation, autoimmunity, chronic inflammatory diseases, regulatory T cells, immune tolerance
Current Pharmaceutical Design
Title:Defective and Excessive Immunities in Pediatric Diseases
Volume: 18 Issue: 35
Author(s): Luigi Daniele Notarangelo and Alberto Tommasini
Affiliation:
Keywords: Primary immunodeficiency diseases, anti-inflammatory drugs, inflammation, autoimmunity, chronic inflammatory diseases, regulatory T cells, immune tolerance
Abstract: Inflammatory and autoimmune diseases are classically considered as disorders arising from hyper-activation of immunity and hence are treated with drugs that suppress the lymphocyte activation and inflammation. Although this strategy has proven useful to cure symptoms, it rarely can heal the disease and long-term treatments are usually needed. Inflammatory and autoimmune diseases frequently occur also in patients with primary immune deficiency disease, proving that immune hyper-activation may paradoxically arise from defective function of immune genes. In these cases, the phenotype of hyper-activation is believed to reflect the attempts of the immune system to compensate for immune defects. Recent data suggest that similar mechanisms could be involved also in the pathogenesis of some multifactorial disorders, such as Crohn’s disease and systemic lupus erythematosus. Based on these considerations, novel therapies could be developed to cure severe autoimmune and inflammatory disorders, not only by aiming to hyper-activation but as well by focusing on the possible underlying immune defects.
Export Options
About this article
Cite this article as:
Daniele Notarangelo Luigi and Tommasini Alberto, Defective and Excessive Immunities in Pediatric Diseases, Current Pharmaceutical Design 2012; 18 (35) . https://dx.doi.org/10.2174/138161212803530943
DOI https://dx.doi.org/10.2174/138161212803530943 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Influence of Culture in Obsessive-compulsive Disorder and Its Treatment
Current Psychiatry Reviews Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging RNA Sensors as a Mechanism of Innate Immune Evasion among SARSCoV2, HIV and Nipah Viruses
Current Protein & Peptide Science Immune Checkpoint Inhibitors and Neurotoxicity
Current Neuropharmacology Anti-Inflammatory Drugs in Psychiatry
Inflammation & Allergy - Drug Targets (Discontinued) SARS-CoV-2 Induced Neurological Manifestations Entangles Cytokine Storm that Implicates for Therapeutic Strategies
Current Medicinal Chemistry The Role of Viruses in Neurodegenerative and Neurobehavioral Diseases
CNS & Neurological Disorders - Drug Targets Cyclooxygenases in the Central Nervous System: Implications for Treatment of Neurological Disorders
Current Pharmaceutical Design Genome Diversity of Emerging Paramyxoviruses
Current Genomics The Role of T and B Cells in Atherosclerosis: Potential Clinical Implications
Current Pharmaceutical Design Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Chikungunya Infection and Immunity: An Overview
Current Immunology Reviews (Discontinued) Clinical Development of Experimental Virus-Mediated Gene Therapy for Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Thiazole Compounds as Antiviral Agents: An Update
Medicinal Chemistry The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Exosomes and the Emerging Field of Exosome-Based Gene Therapy
Current Gene Therapy Animal Models for Obsessive-Compulsive Disorder
Current Neuropharmacology Catatonia: A Brief Update
Current Psychiatry Reviews Synthesis and Biological Activity of Chiral Dihydropyrazole: Potential Lead for Drug Design
Mini-Reviews in Medicinal Chemistry Neuroprotective Effects of Tetracyclines: Molecular Targets, Animal Models and Human Disease
CNS & Neurological Disorders - Drug Targets